CYP19A1 and malignant colon neoplasm: CYP19A1 has been identified as a key player in lipid metabolism and immune microenvironment modulation in colon cancer, with targeting strategies showing promise for enhancing immunotherapy efficacy and serving as a prognostic predictor [58].